[Sho Yoshimoto,Daiki Kato,Satoshi Kamoto,Kie Yamamoto,Masaya Tsuboi,Masahiro Shinada,Namiko Ikeda,Yuiko Tanaka,Ryohei Yoshitake,Shotaro Eto,Kohei Saeki,James Chambers,Yuko Hashimoto,Kazuyuki Uchida,Ryohei Nishimura,Takayuki Nakagawa]
Human epidermal growth factor receptor 2 (HER2) overexpression has been reported in various human cancers. HER2-targeted therapies showed clinical responses in humans with HER2-positive tumors. The incidence of canine primary lung cancer (cPLC) is increasing, but there are no effective systemic therapies for dogs with late-stage cPLC. HER2-targeted therapy could be an option for cPLC, but HER2 expression in cPLC remains unknown. We evaluated HER2 expression in cPLC. Immunohistochemical analysis revealed that 3 samples (19%) scored 3+; 8 (50%), 2+; 5 (31%); and 1+ and 0 (0%), 0. Of the cPLC tissues, 69% were HER2 positive (scored ?2+). These data would lead to further evaluation of the role of HER2 in cPLC as a mechanism of malignancy and therapeutic target.
Research papers (academic journals)
